-
Ferring pharmaceuticals completes phase III study of degarelix in prostate cancer patients
in PRESS RELEASE 2007 onFerring Pharmaceuticals announced today that it has successfully completed the pivotal phase III study for degarelix, its novel prostate cancer treatment…
-
Superior remission rates for once daily use of Pentasa® (mesalazine) in ulcerative colitis
in PRESS RELEASE 2007 onFor the first time a once daily dosing regime of mesalazine (Pentasa® granules) has proven to be statistically superior to…
-
Ferring Pharmaceuticals Forges Worldwide Licensing Agreement for Budesonide MMX™
in PRESS RELEASE 2007 onFerring Pharmaceuticals today announced that it had come to an agreement with Cosmo Pharmaceuticals SpA for…
-
Ferring Pharmaceuticals Announces Board Changes
in PRESS RELEASE 2007 onFerring Pharmaceuticals today announced changes to the company’s Board of Directors. Effective immediately, Alexandra, Countess of Frederiksborg will become a new non-executive member of the Board…
-
New data demonstrates both cost and efficacy benefit of MENOPUR® compared to recombinant FSH treatment
in PRESS RELEASE 2007 onNew data presented today at the European Society of Human Reproduction and Embryology (ESHRE) 2007 congress shows that…
-
Inequality in treatment access remains a key issue for infertile couples across Europe
in PRESS RELEASE 2007 onMedical, political and demographical experts drawn from across the globe have come together this week to discuss the ongoing challenges associated with access to infertility…
PRESS RELEASE 2007
PRESS RELEASE 2007
